Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Journal title: Pharmacological Reports Authors: Aline Brando Lima, Alexandre Machado, Patrícia Simon, Moisés Cavalcante, Daniele Rezende, Gilberto S... Subject(s):
